IHT Wealth Management LLC Grows Position in Bristol-Myers Squibb Co (NYSE:BMY)

IHT Wealth Management LLC raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 42.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,913 shares of the biopharmaceutical company’s stock after acquiring an additional 6,219 shares during the quarter. IHT Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $1,342,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Stonebridge Financial Planning Group LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $26,000. grace capital purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $26,000. Birch Capital Management LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $28,000. Wealthcare Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 47.7% during the 4th quarter. Wealthcare Capital Management LLC now owns 517 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 167 shares during the period. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Bristol-Myers Squibb by 59.1% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 549 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 204 shares during the last quarter. Institutional investors and hedge funds own 77.88% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Barclays assumed coverage on shares of Bristol-Myers Squibb in a research report on Thursday, February 27th. They set an “equal weight” rating and a $69.00 price target for the company. ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Monday, March 9th. Citigroup upgraded shares of Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price target on the stock in a report on Monday, January 6th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $50.00 price target on the stock. in a report on Monday. Finally, Gabelli assumed coverage on shares of Bristol-Myers Squibb in a report on Wednesday, November 27th. They issued a “buy” rating on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $62.08.

In other Bristol-Myers Squibb news, EVP John E. Elicker sold 15,805 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $61.01, for a total transaction of $964,263.05. Following the transaction, the executive vice president now owns 58,666 shares in the company, valued at $3,579,212.66. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Shares of BMY opened at $49.35 on Thursday. The firm has a market cap of $111.16 billion, a PE ratio of 22.53, a price-to-earnings-growth ratio of 0.96 and a beta of 0.78. The company’s fifty day moving average is $60.09 and its two-hundred day moving average is $58.38. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $68.34. The company has a quick ratio of 1.37, a current ratio of 1.60 and a debt-to-equity ratio of 0.84.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.22 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.34. The business had revenue of $7.95 billion for the quarter, compared to the consensus estimate of $6.20 billion. Bristol-Myers Squibb had a net margin of 13.15% and a return on equity of 31.85%. The business’s revenue for the quarter was up 33.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.94 EPS. As a group, equities research analysts anticipate that Bristol-Myers Squibb Co will post 6.15 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Friday, April 3rd will be issued a $0.45 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $1.80 annualized dividend and a yield of 3.65%. Bristol-Myers Squibb’s dividend payout ratio is currently 38.38%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: What are CEFs?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.